Wang et al. found that treatment with an FGF1 variant (FGF1∆HBS) activated AMPK, decreased NR4A1, thereby restoring mitochondrial function and protecting against myocardial remodeling and dysfunction in diabetes (Wang et al., 2021). Here, NR4A1 is linked to diabetes mellitus.